10 companies and organisations from Northern Ireland exhibited at and visited the BIO International Convention, the largest global event for the biotechnology industry.
From developing the world’s first portable defibrillator, to high performance scientific digital cameras, innovation is at the heart of Northern Ireland’s Life and Health Sciences sector.
ARC Regulatory is a medical device consultancy and clinical research organisation that specialises in the delivery of compliant solutions to complex regulatory issues for companies in the companion diagnostic and in vitro diagnostic medical device industries.
Californian based CV6 Therapeutics has established a presence in Belfast to work on a highly innovative R&D project. The project will see CV6 partner with the Centre for Cancer Research and Cell Biology at Queen’s to develop a new drug with the potential to make chemotherapy more effective.
Exploristics provide world-class analytics and specialised software products and statistical services to the pharmaceutical, life sciences and healthcare sectors.
Exploristics has developed the Kerus platform, a cloud-based statistical modelling software dashboard allowing clinical trials planners to simulate trials and interrogate historical data to drive better trial design, reduce cost and accelerate trial reporting.
Fusion Antibodies Limited
Fusion Antibodies offer a range of world-class services in antibody discovery, engineering and supply. They believe in getting better treatments to patients. Using their expertise, services and support they begin each project with the end in mind, helping to deliver the best possible antibodies.
pHion Therapeutics is dedicated to precise and efficient drug delivery for anionic cargo using its peptide-based nanoparticle, termed RALA.
pHion's focus application areas are Vaccine delivery, Ex vivo applications; and Oncology. Partner with pHion on formulation, development and scale up of your therapeutic cargo with RALA to enhance therapeutic efficacy.
ProAxsis specialises in the development of assays for the measurement of active protease biomarkers of disease.
Three activity-based immunoassays are commercially available, targeting the respiratory biomarkers (Neutrophil Elastase (NE), Proteinase 3 and Plasmin), together with a point-of-care test (NEATstik®), to enable ongoing monitoring of active NE levels.
Queen's University Belfast Enterprise & Research
The Commercial Development Team at Queen’s University Belfast has responsibility for IP management, partnering, and negotiations relating to licensing of University technology and support for spin-out company formation.
A report for the Department for Business, Energy, and Industrial Strategy (BEIS) placed Queen’s in the highest group for knowledge exchange and commercialisation, which includes the Institute of Cancer Research, and the Universities of Cambridge, Oxford, and Queen’s University Belfast.
Randox is a global leader in healthcare diagnostics and is the UK’s largest diagnostic company, exporting over 95% of its products worldwide. Randox products and services are used in hospitals, clinical, research and molecular laboratories, food testing, forensic toxicology, life sciences, and veterinary laboratories.
SiSaf is a commercial stage drug/product development biopharmaceutical company, focussed on the commercialisation of products based upon its proprietary ProSilic platform delivery technology.
Our pharmaceutical pipeline is focussed on reformulating existing medicines to make them more effective. It develops formulations for clients, our own subsidiaries and grant-funded R&D projects.